Testing Tobacco Products Promoted to Reduce Harm (R21)

The summary for the Testing Tobacco Products Promoted to Reduce Harm (R21) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Testing Tobacco Products Promoted to Reduce Harm (R21): Purpose. This funding opportunity announcement (FOA), issued by the National Cancer Institute (NCI) and the National Institute on Drug Abuse (NIDA), invites applications that propose multidisciplinary research on potential reduced-exposure tobacco products, both smoked and smokeless. The multidisciplinary studies can span basic, biological, behavioral, surveillance, and epidemiology research. The tobacco industry is currently promoting several new products with claims that they: a) are less either harmful or less addictive; and b) purportedly deliver lower amounts of toxic, carcinogenic, and/or addictive agents to the user compared with conventional products. However, to date, the scientific evidence is insufficient to evaluate whether these new products actually reduce the users exposure or risk for tobacco-related diseases. The overarching goal of this FOA is to determine whether potential reduced-exposure tobacco products provide a truly, less-harmful alternative to conventional tobacco products, both at the individual and population level. Mechanism of Support. This FOA utilizes the NIH exploratory/developmental (R21) grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-09-046, which uses the NIH Research Project Grant (R01) mechanism. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications; therefore, the anticipated number of awards is not known Budget and Project Period. The total project period for an application submitted in response to this funding opportunity may not exceed two years. Direct costs are limited to $275,000 over an R21 two-year period, with no more than $200,000 in direct costs allowed in any single year. Research Plan Component Length: Items 2-5 of the PHS398 Research Plan component of the R21 application may not exceed 15 pages, including tables, graphs, figures, diagrams, and charts. For information on NIH Exploratory/Developmental Research Grant Award (R21). Eligible Institutions/Organizations. Institutions/organizations listed in Section III, 1.A. are eligible to apply. Eligible Project Directors/Principal Investigators (PDs/PIs). Include Individuals with the skills, knowledge, and resources necessary to carry out the proposed research are invited to work with their institution/organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. Number of PDs/PIs. More than one PD/PI (i.e., multiple PDs/PIs), may be designated on the application. Number of Applications. Applicants may submit more than one application, provided that each application is scientifically distinct. Resubmissions. Applicants may submit a resubmission application, but such application must include an Introduction addressing the previous peer review critique (Summary Statement).See new NIH policy on resubmission (amended) applications (NOT-OD-09-003, NOT-OD-09-016).